ATE447968T1 - Impfung mit immunisolierten und einen immunomodulator produzierenden zellen - Google Patents

Impfung mit immunisolierten und einen immunomodulator produzierenden zellen

Info

Publication number
ATE447968T1
ATE447968T1 AT03759977T AT03759977T ATE447968T1 AT E447968 T1 ATE447968 T1 AT E447968T1 AT 03759977 T AT03759977 T AT 03759977T AT 03759977 T AT03759977 T AT 03759977T AT E447968 T1 ATE447968 T1 AT E447968T1
Authority
AT
Austria
Prior art keywords
immunomodulator
vaccination
cells producing
relates
immune
Prior art date
Application number
AT03759977T
Other languages
English (en)
Inventor
Nicolas Mach
Original Assignee
Maxivax Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxivax Sa filed Critical Maxivax Sa
Application granted granted Critical
Publication of ATE447968T1 publication Critical patent/ATE447968T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03759977T 2002-06-17 2003-06-17 Impfung mit immunisolierten und einen immunomodulator produzierenden zellen ATE447968T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02013249A EP1374893A1 (de) 2002-06-17 2002-06-17 Impfung mit Immuno-isolierten Zellen die einen Immunomodulator Produzieren
PCT/EP2003/007140 WO2003105895A1 (en) 2002-06-17 2003-06-17 Vaccination with immuno-isolated cells producing an immunomodulator

Publications (1)

Publication Number Publication Date
ATE447968T1 true ATE447968T1 (de) 2009-11-15

Family

ID=29716769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03759977T ATE447968T1 (de) 2002-06-17 2003-06-17 Impfung mit immunisolierten und einen immunomodulator produzierenden zellen

Country Status (8)

Country Link
US (3) US20060024318A1 (de)
EP (3) EP1374893A1 (de)
AT (1) ATE447968T1 (de)
AU (1) AU2003246369A1 (de)
DE (1) DE60330004D1 (de)
DK (2) DK2147682T3 (de)
ES (2) ES2335490T3 (de)
WO (1) WO2003105895A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8180920B2 (en) * 2006-10-13 2012-05-15 Rgb Networks, Inc. System and method for processing content
WO2009125332A1 (en) * 2008-04-07 2009-10-15 Peter Bromley New and safe procedure for immunization against infectious diseases agents
US8551749B2 (en) * 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
EP3352783B1 (de) 2015-09-25 2021-08-25 MaxiVAX SA Impfstoff, der einen immunomodulator produzierende immunoisolierte zellen enthält
WO2018044888A1 (en) * 2016-08-29 2018-03-08 Chen James C Tumor vaccination systems, devices, and methods
WO2022027020A2 (en) * 2020-07-27 2022-02-03 Arizona Board Of Regents On Behalf Of Arizona State University Artificial placenta vaccine for organ transplantation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5955095A (en) * 1992-04-22 1999-09-21 Brown University Research Foundation Microporous macrocapsules
MX9304089A (es) * 1992-07-08 1994-01-31 Schering Corp Uso de gm-csf como una vacuna adyuvante.
CA2178902A1 (en) * 1993-12-14 1995-06-22 Drew Pardoll Controlled release of pharmaceutically active substances for immunotherapy
AU4818297A (en) 1996-10-16 1998-05-11 Johns Hopkins University, The Cytokine enhanced immunotherapy for brain tumors
ATE371463T1 (de) 1997-02-05 2007-09-15 Jean-Claude Bystryn Ph-sensitive liposomen und andere typen immunomodulatoren enthaltender gekapselter impfstoffe sowie herstellungs- und anwendungsverfahren dafür
ATE264911T1 (de) * 1998-02-02 2004-05-15 Univ Johns Hopkins Med Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen
US7250291B1 (en) * 1998-08-07 2007-07-31 Dana-Farber Cancer Institute Tumor antigens and uses thereof
CN100425287C (zh) * 1999-02-09 2008-10-15 理化学研究所 肿瘤疫苗
ATE360063T1 (de) * 2000-10-12 2007-05-15 Agency Science Tech & Res Nicht störendes, dreidimensionales system für die kultivierung und ernte verankerungsabhängiger zellen
FR2822707A1 (fr) * 2001-04-03 2002-10-04 Neurotech Association d'un antigene tumoral et d'un systeme de delivrance d'une cytokine ou d'une chemokine a des fins d'immunotherapie du cancer
CA2485259A1 (en) * 2002-05-07 2003-11-20 Mcmaster University Microcapsules containing biomedical materials

Also Published As

Publication number Publication date
EP1513551B1 (de) 2009-11-11
US20140341982A1 (en) 2014-11-20
DK2147682T3 (en) 2016-02-01
US20060024318A1 (en) 2006-02-02
EP1374893A1 (de) 2004-01-02
DK1513551T3 (da) 2010-03-08
EP2147682A2 (de) 2010-01-27
US9814682B2 (en) 2017-11-14
WO2003105895A1 (en) 2003-12-24
EP2147682B1 (de) 2015-11-11
EP1513551A1 (de) 2005-03-16
ES2560105T3 (es) 2016-02-17
ES2335490T3 (es) 2010-03-29
EP2147682A3 (de) 2012-07-25
US20080107686A1 (en) 2008-05-08
DE60330004D1 (de) 2009-12-24
AU2003246369A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
HK1083635A1 (en) Animal protein free media for cultivation of cells
CY1113044T1 (el) Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων
WO2004058157A3 (en) Yeast-based vaccines as immunotherapy
ATE461709T1 (de) Choline-bindende proteine derivate aus pneumokoken als impfstoff
DE602004028468D1 (de) Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
ATE460944T1 (de) Verfahren und zusammensetzungen zur herstellung und steuerung des effektorprofils von t-zellen durch gleichzeitiges beladen und aktivieren ausgewählter untergruppen von antigen- präsentierenden zellen
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
EP2385060A3 (de) Verfahren und Zusammensetzungen zum Auslösen von multivalenten Immunreaktionen gegen auf Krebszellen und Tumor-Stroma exprimierte dominante und subdominante Epitope
MXPA05008340A (es) Microbios de vida libre modificados, composiciones de vacuna y metodos de uso de los mismos.
ATE439375T1 (de) Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
DE69030172D1 (de) Impfstoffe gegen Krebs und Infektionskrankheiten
JP2008512491A5 (de)
EA200301097A1 (ru) Иммунотерапевтические комбинации для лечения опухолей, которые сверхэкспрессируют ганглиозиды
ATE441420T1 (de) Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
ATE447968T1 (de) Impfung mit immunisolierten und einen immunomodulator produzierenden zellen
ATE460943T1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
WO2005035558A3 (en) Piscirickettsia salmonis antigens and use thereof
ATE431156T1 (de) Verwendung des neutrophil-activating-protein von helicobacter pylori und/oder teile davon als adjuvant für die induktion einer t-helper type 1 (th1) immunantwort
DE502004005784D1 (de) Mittel zur behandlung von infektionen mit leishmanien
WO2003066833A3 (en) Use of recombinant hepatitis b core particles to develop vaccines against infectious pathogens and malignancies
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
DE60227367D1 (de) Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
PL358081A1 (en) Inclusion bodies as antigenes in oral immunization of animals
WO2004000213A3 (en) Method for growing human organs, treating diseases, and increasing longevity
ES2172482B1 (es) Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1513551

Country of ref document: EP